Reference health

Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?

https://doi.org/10.1146/annurev-micro-090817-062535
CiteStamped reference-health badge
85/85 checkable references clean · checked 2026-07-22

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 85 checked references that resolve
resolves10.1016/j.cels.2015.08.013
Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing
resolves10.3389/fmicb.2016.00474
Biocontrol and Rapid Detection of Food-Borne Pathogens Using Bacteriophages and Endolysins
resolves10.1111/j.1572-0241.2006.00856.x
Practice Guidelines in Acute Pancreatitis
resolves10.1128/AAC.03183-14
Characterization of a P1-Like Bacteriophage Carrying an SHV-2 Extended-Spectrum β-Lactamase from an Escherichia coli Strain
resolves10.1016/B978-0-12-394621-8.00014-5
Bacteriophage-Encoded Bacterial Virulence Factors and Phage–Pathogenicity Island Interactions
resolves10.1093/emph/eoy005
Phage treatment of an aortic graft infected with<i>Pseudomonas aeruginosa</i>
resolves10.1111/j.1574-6968.1989.tb03415.x
Conversion of<i>Salmonella enteritidis</i>phage type 4 to phage type 7 involves loss of lipopolysaccharide with concomitant loss of virulence
resolves10.1016/j.mib.2014.05.022
Bacteriophage-based synthetic biology for the study of infectious diseases
resolves10.4161/bact.1.1.14942
Phages in nature
resolves10.1001/jama.1933.02740200037014
COMMERCIAL ASPECTS OF BACTERIOPHAGE THERAPY
resolves10.1016/S0021-9258(18)68927-6
Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage.
resolves10.1038/nrg3226
Transforming clinical microbiology with bacterial genome sequencing
resolves10.1016/j.jhealeco.2016.01.012
Innovation in the pharmaceutical industry: New estimates of R&amp;D costs
resolves10.1016/0022-2836(75)90321-6
Structure and physico-chemical properties of bacteriophage G
resolves10.1001/jama.1934.72750510005009
BACTERIOPHAGE THERAPY
resolves10.1038/nature09929
A system for the continuous directed evolution of biomolecules
resolves10.1073/pnas.97.21.11455
Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration
resolves10.1038/246221a0
Fate of Bacteriophage Lambda in Non-immune Germ-free Mice
resolves10.2174/138920110790725311
Phage Choice, Isolation, and Preparation for Phage Therapy
resolves10.1001/jama.290.11.1510
Update on Syphilis
resolves10.4161/bact.21440
Development of a high throughput assay for indirectly measuring phage growth using the OmniLog<sup>TM</sup>system
resolves10.1056/NEJMra021333
The Pathophysiology and Treatment of Sepsis
resolves10.1128/AEM.01848-10
Wide Host Range and Strong Lytic Activity of<i>Staphylococcus</i><i>aureus</i>Lytic Phage Stau2
resolves10.4049/jimmunol.76.3.209
The Presence in Normal Serum of Specific Antibody Against Bacteriophage T4 and Its Increase During the Earliest Stages of Immunization
resolves10.1001/jama.1946.02870380016006
TREATMENT OF TYPHOID FEVER WITH TYPE SPECIFIC BACTERIOPHAGE
resolves10.1128/JB.01311-10
Evolutionarily Conserved Orthologous Families in Phages Are Relatively Rare in Their Prokaryotic Hosts
resolves10.1007/s12250-014-3557-0
Experience of the Eliava Institute in bacteriophage therapy
resolves10.1016/j.medmal.2008.06.023
Phage therapy experience at the Eliava Institute
resolves10.1038/nrmicro2315
Bacteriophage resistance mechanisms
resolves10.1093/ofid/ofy064
Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection
resolves10.1038/nrd3560
Antibacterial R&amp;D incentives
resolves10.1093/cid/cis385
Impact of Appropriate Antimicrobial Therapy on Mortality Associated With Acinetobacter baumannii Bacteremia: Relation to Severity of Infection
resolves10.3389/fmicb.2015.00343
Virulence reduction in bacteriophage resistant bacteria
resolves10.1016/j.idc.2009.06.008
Pharmacokinetics and Pharmacodynamics of Antibacterial Agents
resolves10.1177/09680519000060010401
A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis
resolves10.1089/vim.2013.0128
Phage Neutralization by Sera of Patients Receiving Phage Therapy
resolves10.3390/v10100537
High Throughput Manufacturing of Bacteriophages Using Continuous Stirred Tank Bioreactors Connected in Series to Ensure Optimum Host Bacteria Physiology for Phage Production
resolves10.1007/s11999-009-0738-5
Treatment of War Wounds: A Historical Review
resolves10.1201/b16471
FDA Regulatory Affairs
resolves10.1371/journal.pone.0003957
BRED: A Simple and Powerful Tool for Constructing Mutant and Recombinant Bacteriophage Genomes
resolves10.1001/archinte.1923.00110240092005
THE BACTERIOPHAGE IN THE TREATMENT OF INFECTIONS
resolves10.1073/pnas.93.8.3188
Long-circulating bacteriophage as antibacterial agents.
resolves10.1038/nrd1111
The prospect for bacteriophage therapy in Western medicine
resolves10.1126/science.1214449
Repeatability and Contingency in the Evolution of a Key Innovation in Phage Lambda
resolves10.1016/B978-0-12-394438-2.00003-7
Clinical Aspects of Phage Therapy
resolves10.1189/jlb.3RU0316-151R
Endotoxemia—menace, marker, or mistake?
resolves10.1128/AEM.71.4.1836-1842.2005
Potential of the Polyvalent Anti- <i>Staphylococcus</i> Bacteriophage K for Control of Antibiotic-Resistant Staphylococci from Hospitals
resolves10.1128/JVI.02457-16
Klebsiella Phage ΦK64-1 Encodes Multiple Depolymerases for Multiple Host Capsular Types
resolves10.1006/viro.1998.9203
The Polyvalent Staphylococcal Phage φ812:Its Host-Range Mutants and Related Phages
resolves10.1016/j.mayocp.2016.06.020
New Developments in Clinical Bacteriology Laboratories
resolves10.1038/nature08798
Antagonistic coevolution accelerates molecular evolution
resolves10.1007/s10865-018-9948-1
Impact of time perspectives on texting intervention to reduce HIV/STI transmission among female sex workers in Tijuana and Ciudad Juarez, Mexico
resolves10.1016/j.mib.2014.11.019
Bacteriophage-mediated spread of bacterial virulence genes
resolves10.3390/v10040188
Characterizing Phage Genomes for Therapeutic Applications
resolves10.1186/s12889-018-5946-z
Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention
resolves10.1177/0956462418793038
Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region
resolves10.1371/journal.pone.0201954
Factors associated with program effectiveness in the implementation of a sexual risk reduction intervention for female sex workers across Mexico: Results from a randomized trial
resolves10.1073/pnas.1320538111
Staphylococcal pathogenicity island DNA packaging system involving <i>cos</i> -site packaging and phage-encoded HNH endonucleases
resolves10.1128/AAC.02877-15
Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections
resolves10.1093/cid/cix188
Phage Therapy: Considerations and Challenges for Development
resolves10.1097/CCM.0000000000002255
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
resolves10.1097/00000441-193003000-00005
THE USE OF BACTERIOPHAGE FILTRATES IN THE TREATMENT OF SUPPURATIVE CONDITIONS
resolves10.1038/nrmicro3096
Revenge of the phages: defeating bacterial defences
resolves10.1093/molbev/msv032
Coevolution with Bacteriophages Drives Genome-Wide Host Evolution and Constrains the Acquisition of Abiotic-Beneficial Mutations
resolves10.1001/archpedi.1932.01950110115011
STAPHYLOCOCCUS AUREUS MENINGITIS
resolves10.1111/j.1574-6968.1999.tb13381.x
Transduction of multiple drug resistance of<i>Salmonella enterica</i>serovar<i>typhimurium</i>DT104
resolves10.1128/AAC.00954-17
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection
resolves10.4049/jimmunol.94.6.833
Relationship between Blood Clearance and Viruria after Intravenous Injection of Mice and Rats with Bacteriophage and Polioviruses
resolves10.1021/sb300049p
Genome Replication, Synthesis, and Assembly of the Bacteriophage T7 in a Single Cell-Free Reaction
resolves10.2146/090087a
Guidelines and quality for community-acquired pneumonia: Measures from the Joint Commission and the Centers for Medicare and Medicaid Services
resolves10.1086/315306
Differential Antibiotic‐Induced Endotoxin Release in Severe Melioidosis
resolves10.1111/1574-6968.12402
Impact of the cell life-cycle on bacteriophage T4 infection
resolves10.1056/NEJM198908033210503
The Cardiovascular Response of Normal Humans to the Administration of Endotoxin
resolves10.1146/annurev.micro.55.1.437
Bacteriophage Therapy
resolves10.4161/bact.20757
The strange history of phage therapy
resolves10.1016/j.mib.2015.08.005
In the midst of the antimicrobial discovery conundrum: an overview
resolves10.1001/archopht.1932.00820180055005
BACTERIOPHAGE IN OPHTHALMOLOGY
resolves10.1016/S0140-6736(01)20383-3
AN INVESTIGATION ON THE NATURE OF ULTRA-MICROSCOPIC VIRUSES.
resolves10.1016/j.virusres.2005.05.014
An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold
resolves10.1038/ncomms14187
A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models
resolves10.1007/s12275-014-4087-z
Phage lysis: Three steps, three choices, one outcome
resolves10.1126/science.aad6791
Phage therapy redux—What is to be done?
resolves10.3389/fmicb.2017.00403
Jumbo Bacteriophages: An Overview
resolves10.1016/j.bmc.2016.11.008
Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents
resolves10.1002/path.1700640402
Hypoplasia of the exocrine tissue of the pancreas
The 6 references without a DOI — listed, not checked
no DOI — not checkedB6
no DOI — not checkedB13
no DOI — not checkedAn Introduction to Genetic Analysis
no DOI — not checkedMark Twain: A Biography
no DOI — not checkedB63
no DOI — not checkedMolecular Biology of Bacterial Viruses
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1146/annurev-micro-090817-062535"><img src="https://citestamp.com/citestamped/10.1146/annurev-micro-090817-062535/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1146/annurev-micro-090817-062535/badge.svg)](https://citestamp.com/citestamped/10.1146/annurev-micro-090817-062535)